This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio
by Zacks Equity Research
Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.
REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status
by Zacks Equity Research
REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.
Regenxbio (RGNX)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Regenxbio (RGNX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -57.47% and -37.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Can Regenxbio (RGNX) Climb 77% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 77.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win
by Kinjel Shah
AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.
REGENXBIO (RGNX) Stock Up on Collaboration Deal With AbbVie
by Zacks Equity Research
REGENXBIO (RGNX) enters into a strategic partnership with AbbVie to co-develop and commercialize RGX-314, a potential gene therapy for retinal indications. Resultantly, REGENXBIO's share price surges.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal
by Kinjel Shah
The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others
REGENXBIO (RGNX) Moves 31.2% Higher: Will This Strength Last?
by Zacks Equity Research
REGENXBIO (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -25.93% and -20.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Regenxbio (RGNX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -6.19% and -32.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for March 24th
by Zacks Equity Research
IHG, NNN, PRMW, RGNX, and WW have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2021
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -211.71% and -83.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program
by Zacks Equity Research
REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals
4 Biotechs That Could Be Potential Acquisition Targets in 2021
by Zacks Equity Research
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Enlivex (ENLV) This Earnings Season?
by Zacks Equity Research
Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.
Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.
Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.
Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?
by Zacks Equity Research
Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.
Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.